The NLRP3 inflammasome and diabetic cardiomyopathy : editorial to: "Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model" by Beibei Luo et al.
Department of Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, MI, 48201, USA, plsingh@med.wayne.edu.
Lalit P
LP
Singh
D000818:Animals; D002352:Carrier Proteins; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D058065:Diabetic Cardiomyopathies / Q000188:drug therapy*; D005464:Fluorobenzenes / Q000494:pharmacology*; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; D011743:Pyrimidines / Q000494:pharmacology*; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000494:pharmacology*
D002352:Carrier Proteins; D005464:Fluorobenzenes; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; C573346:Nlrp3 protein, rat; D011743:Pyrimidines; D018160:Receptors, Cytoplasmic and Nuclear; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium